TriSalus Life Sciences Inc., a medical technology company with a market capitalization of $158 million, reported a robust performance in Q1 2025, with net sales reaching $9.2 million, marking a 42% increase year-over-year. Despite a slight dip in gross margin, the company reported reduced operating losses and announced significant strides in product development and market expansion. The stock price closed at $4.9, reflecting a 3.35% decrease.
Key Takeaways
- TriSalus Life Sciences reported a 42% year-over-year increase in net sales.
- The company reduced operating losses significantly compared to the previous year.
- Newly launched products and market expansions are expected to drive future growth.
- TriSalus anticipates at least 50% revenue growth in 2025.
Company Performance
TriSalus Life Sciences demonstrated strong growth in Q1 2025, driven by a strategic focus on expanding its product portfolio and market presence. The company achieved a 10% market share in liver procedures and is making inroads into new clinical applications. This performance is indicative of the company’s aggressive growth strategy in the competitive interventional oncology space.
Financial Highlights
- Revenue: $9.2 million, up 42% year-over-year and 11% sequentially.
- Gross margin: 84%, slightly down from 85% in Q1 2024.
- Operating losses: $7.3 million, an improvement from $11.7 million in Q1 2024.
- Adjusted EBITDA losses: $5.5 million, compared to $10.4 million in Q1 2024.
- Cash and cash equivalents: $13 million, with an additional $22 million raised in a private placement.
Outlook & Guidance
TriSalus is targeting at least 50% revenue growth in 2025, driven by new product launches and market expansion. The company is investing in its sales force and clinical applications, although it does not expect to achieve EBITDA or cash flow positivity until early 2026. The focus remains on strengthening clinical evidence and expanding partnerships, particularly for the drug nalatolimod.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.